About
Nimish Shah sits down with Andy Robbins, CEO of Cogent Biosciences, for a candid conversation about building a targeted therapy company in oncology. Andy shares how Cogent made high-stakes decisions around bezuclastinib, why speed matters in biotech, and what it takes to build conviction years before clinical answers arrive. They also dig into what's overhyped, what's undervalued, and why the best biotech leaders stay humble, fast-moving, and relentlessly focused on patients.